If you have been reading about HGF/c-Met and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
The longest word in Toki Pona is kijetesantakalu (15 letters), which was proposed in 2009 as an April Fools' joke by the language's creator Sonja Lang as a word for any animal of the Procyonidae family, which includes raccoons and related species. The word has since entered into common use, and it has become common to define kijetesantakalu more broadly as any animal from the Musteloidea superfamily. In 2019 James Flear designed a glyph for kijetesantakalu in Toki Pona's Sitelen Pona writing system, which has become a popular icon within the Toki Pona community. As a minimalistic isolating constructed language, most words in Toki Pona are much shorter, the median being 4 letters. The longest words featured in the 2014 book Toki Pona: The Language of Good, Lang's first official Toki Pona publication, are the 7-letter words kepeken ("to use, by means of") and sitelen ("symbol, picture"). The list of proposed country names in the same book also mentions ma Papuwanijukini ("Papua New Guinea"), which includes a 14-letter proper adjective.
==== Polymerase chain reactions ==== Thermostable DNA polymerases such as Taq polymerase and Pfu DNA polymerase are used in polymerase chain reactions (PCR) where temperatures of 94 °C or over are used to melt DNA strands in the denaturation step of PCR. This resistance to high temperature allows for DNA polymerase to elongate DNA with a desired sequence of interest with the presence of dNTPs.
According to Pahnke, these categories "describe the core of a universal psychological experience, free from culturally determined philosophical or theological interpretations", and allow researchers to assess mystical experiences on a qualitative, numerical scale. In the 1962 Marsh Chapel Experiment, run by Pahnke at the Harvard Divinity School under Leary's supervision, almost all the graduate degree divinity student volunteers who received psilocybin reported profound religious experiences. One of the participants was religious scholar Huston Smith, author of several textbooks on comparative religion; he called his experience "the most powerful cosmic homecoming I have ever experienced." In a 25-year followup to the experiment, all the subjects given psilocybin said their experience had elements of "a genuine mystical nature and characterized it as one of the high points of their spiritual life". Psychedelic researcher Rick Doblin considered the study partially flawed due to incorrect implementation of the double-blind procedure and several imprecise questions in the mystical experience questionnaire. Nevertheless, he said that the study cast "considerable doubt on the assertion that mystical experiences catalyzed by drugs are in any way inferior to non-drug mystical experiences in both their immediate content and long-term effects". Psychiatrist William A.
Sources: en.wikipedia.org
{\displaystyle {\begin{aligned}&\partial _{t}S=D_{S}\nabla ^{2}S-{\frac {\beta IS}{N}},\\[6pt]&\partial _{t}I=D_{I}\nabla ^{2}I+{\frac {\beta IS}{N}}-\gamma I,\\[6pt]&\partial _{t}R=D_{R}\nabla ^{2}R+\gamma I,\end{aligned}}}
Serous acinar cells are roughly pyramid shape, with the apex of the pyramid pointing towards to the center of the (roughly spherical) acinus. Inside of the cell on the side with the apex, there are specialize saliva-material containing structures called secretory granules. Compared to mucous acinar cells, their nuclei is more round, and centrally located.
The production of copra – removing the shell, breaking it up, drying – is usually done where the coconut palms grow. Copra can be made by smoke drying, sun drying, or kiln drying. Hybrid solar drying systems can also be used for a continuous drying process. In a hybrid solar drying system, solar energy is utilized during daylight and energy from burning biomass is used when sunlight is not sufficient or during night time. Sun drying requires little more than racks and sufficient sunlight. Halved nuts are drained of water, and left with the meat facing the sky; they can be washed to remove mold-creating contaminants. After two days the meat can be removed from the shell with ease, and the drying process is complete after three to five more days (up to seven in total). Sun drying is often combined with kiln drying, eight hours of exposure to sunlight means the time spent in a kiln can be reduced by a day and the hot air the shells are exposed to in the kiln is more easily able to remove the remaining moisture. This process can also be done in reverse order: partially drying the copra in the kiln, and finishing the process with sunlight. Starting with sun drying requires careful inspection to avoid contamination with mold while starting with kiln-drying can harden the meat and prevent it from drying out completely in the sun. In India, small but whole coconuts can be dried over the course of eight months to a year, and the meat inside removed and sold as a whole ball. Meat prepared in this fashion is sweet, soft, oily and is cream-coloured instead of being white.
Sources: en.wikipedia.org
It has been suggested that snakes evolved the mechanisms necessary for venom formation and delivery sometime during the Miocene epoch. During the mid-Tertiary, most snakes were large ambush predators belonging to the superfamily Henophidia, which use constriction to kill their prey. As open grasslands replaced forested areas in parts of the world, some snake families evolved to become smaller and thus more agile. However, subduing and killing prey became more difficult for the smaller snakes, leading to the evolution of snake venom. The most likely hypothesis holds that venom glands evolved from specialized salivary glands. The venom itself evolved through the process of natural selection; it retained and emphasized the qualities that made it useful in killing or subduing prey. Today we can find various snake species in stages of this hypothesized development. There are the highly efficient envenoming machines - like the rattlesnakes - with large capacity venom storage, hollow fangs that swing into position immediately before the snake bites, and spare fangs ready to replace those damaged or lost. Other research on Toxicofera, a hypothetical clade thought to be ancestral to most living reptiles, suggests an earlier time frame for the evolution of snake venom, possibly to the order of tens of millions of years, during the Late Cretaceous. Snake venom is produced in modified parotid glands normally responsible for secreting saliva. It is stored in structures called alveoli behind the animal's eyes and ejected voluntarily through its hollow tubular fangs.
During the 80th session of the UN General Assembly in September 2025, Trump met in New York a group of leaders of several Arab states to discuss the situation of the Gaza Strip. Reportedly, he presented them with a 21-point plan that called for ending the war and ending Hamas rule over the strip while establishing an international Arab military force to control the area for a period of three years. He also assured them that he would not allow Israel to annex the West Bank. In late September 2025, Israeli and British media reported a proposal by former British prime minister Tony Blair for a Gaza International Transitional Authority to administer the Gaza Strip for a transitional period, before turning over administration to the Palestinian Authority.
==== Release of endorphins or adenosine ==== Some modern practitioners support the use of acupuncture to treat pain, but have abandoned the use of qi, meridians, yin, yang and other mystical energies as an explanatory frameworks. The use of qi as an explanatory framework has been decreasing in China, even as it becomes more prominent during discussions of acupuncture in the US. Many acupuncturists attribute pain relief to the release of endorphins when needles penetrate, but no longer support the idea that acupuncture can affect a disease. Some studies suggest acupuncture causes a series of events within the central nervous system, and that it is possible to inhibit acupuncture's analgesic effects with the opioid antagonist compound naloxone, suggesting that the use of acupuncture may trigger the release of endogenous opioids. Mechanical deformation of the skin by acupuncture needles appears to result in the release of adenosine. The anti-nociceptive effect of acupuncture may be mediated by the adenosine A1 receptor. A 2014 review in Nature Reviews Cancer analyzed mouse studies that suggested acupuncture relieves pain via the local release of adenosine, which then triggered nearby A1 receptors. The review found that in those studies, because acupuncture "caused more tissue damage and inflammation relative to the size of the animal in mice than in humans, such studies unnecessarily muddled a finding that local inflammation can result in the local release of adenosine with analgesic effect."
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.